RECOMBINANT VIRUS ASSAY - A RAPID, PHENOTYPIC ASSAY FOR ASSESSMENT OF DRUG SUSCEPTIBILITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES

被引:169
作者
KELLAM, P
LARDER, BA
机构
[1] Antiviral Therapeutic Research Unit, Wellcome Research Laboratories, Langley Ct., Beckenham, Kent BR3 3BS, South Eden Park Rd.
关键词
D O I
10.1128/AAC.38.1.23
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Antiviral drug susceptibility assays for clinical human immunodeficiency virus type 1 (HIV-1) isolates are required to monitor the development of drug resistance during clinical trials and antiretroviral drug therapy. First-generation phenotypic assays possess a number of drawbacks, not least the selection of unrepresentative virus populations during cocultivation. Here we describe a rapid phenotypic assay for the assessment of the susceptibility of clinical isolates to reverse transcriptase (RT) inhibitors. This procedure, called the recombinant virus assay, allows the generation of viable virus by homologous recombination of a PCR-derived pool of RT coding sequences into an RT-deleted, noninfectious proviral clone, pHIVDELTABstEII. A nested PCR procedure has been optimized to allow the amplification of an RT pool from both uncultured and cocultured infected patient peripheral blood lymphocyte (PBL) DNA for subsequent use in the creation of recombinant viruses. Analysis of two patients during the course of zidovudine therapy showed that this approach produced viruses which accurately exhibited the same genotype and phenotype as that of the original infected PBL DNA. The recombinant virus assay can be performed in approximately 3 weeks without the use of donor PBLs and therefore represents a rapid, nonselective procedure for the assay of clinical isolates.
引用
收藏
页码:23 / 30
页数:8
相关论文
共 51 条
[1]   HIV-1-SPECIFIC REVERSE-TRANSCRIPTASE INHIBITORS SHOW DIFFERENTIAL ACTIVITY AGAINST HIV-1 MUTANT STRAINS CONTAINING DIFFERENT AMINO-ACID SUBSTITUTIONS IN THE REVERSE-TRANSCRIPTASE [J].
BALZARINI, J ;
KARLSSON, A ;
PEREZPEREZ, MJ ;
VRANG, L ;
WALBERS, J ;
ZHANG, H ;
OBERG, B ;
VANDAMME, AM ;
CAMARASA, MJ ;
DECLERCQ, E .
VIROLOGY, 1993, 192 (01) :246-253
[2]   RECOMBINATION OF TRANSFECTED DNAS IN VERTEBRATE CELLS IN CULTURE [J].
BANDYOPADHYAY, PK ;
WATANABE, S ;
TEMIN, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (11) :3476-3480
[3]   ZIDOVUDINE SENSITIVITY OF HUMAN IMMUNODEFICIENCY VIRUSES FROM HIGH-RISK, SYMPTOM-FREE INDIVIDUALS DURING THERAPY [J].
BOUCHER, CAB ;
TERSMETTE, M ;
LANGE, JMA ;
KELLAM, P ;
DEGOEDE, REY ;
MULDER, JW ;
DARBY, G ;
GOUDSMIT, J ;
LARDER, BA .
LANCET, 1990, 336 (8715) :585-590
[4]   ORDERED APPEARANCE OF ZIDOVUDINE RESISTANCE MUTATIONS DURING TREATMENT OF 18 HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS [J].
BOUCHER, CAB ;
OSULLIVAN, E ;
MULDER, JW ;
RAMAUTARSING, C ;
KELLAM, P ;
DARBY, G ;
LANGE, JMA ;
GOUDSMIT, J ;
LARDER, BA .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) :105-110
[5]   DEVELOPMENT OF A SENSITIVE QUANTITATIVE FOCAL ASSAY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTIVITY [J].
CHESEBRO, B ;
WEHRLY, K .
JOURNAL OF VIROLOGY, 1988, 62 (10) :3779-3788
[6]   HIV INHIBITORS TARGETED AT THE REVERSE-TRANSCRIPTASE [J].
DECLERCQ, E .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (02) :119-137
[7]  
DESAINTVINCENT BR, 1983, P NATL ACAD SCI-BIOL, V80, P2002
[8]   SUSCEPTIBILITY TESTING BY POLYMERASE CHAIN-REACTION DNA QUANTITATION - A METHOD TO MEASURE DRUG-RESISTANCE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].
ERON, JJ ;
GORCZYCA, P ;
KAPLAN, JC ;
DAQUILA, RT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (08) :3241-3245
[9]  
EUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713
[10]   A MOLECULAR CLONE OF HTLV-III WITH BIOLOGICAL-ACTIVITY [J].
FISHER, AG ;
COLLALTI, E ;
RATNER, L ;
GALLO, RC ;
WONGSTAAL, F .
NATURE, 1985, 316 (6025) :262-265